Michael Luo

Antares Pharma's Otrexup Will Gain FDA Approval And Generate Positive EPS

Investment Thesis

Antares Pharma (NASDAQ:ATRS) is an under the radar biotech company which is starting to make the significant transformation of a royalty based revenue generating company to a fully fledged proprietary product revenue generating bonafide biotech. Its first proprietary product Otrexup has an FDA PDUFA date of October 14, 2013. I am confident that the FDA will approve Otrexup. The biggest bear case against Antares is seeing if management can execute its plan and generate Otrexup revenue, which can organically fund the promising pipeline. This article will feature my investing thesis on why Otrexup will gain FDA approval, why Otrexup commercialization will be incredibly successful and how Antares management will be able to leverage Otrexup gains to...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details